The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma.
G. Anandappa
No relevant relationships to disclose
E. Sala
No relevant relationships to disclose
H. K. Cheow
No relevant relationships to disclose
N. J. Bird
No relevant relationships to disclose
A. Shaw
No relevant relationships to disclose
A. N. Priest
No relevant relationships to disclose
A. Gill
No relevant relationships to disclose
T. Fryer
No relevant relationships to disclose
Y. T. Hong
No relevant relationships to disclose
R. Smith
No relevant relationships to disclose
A. Backen
No relevant relationships to disclose
B. Whitcher
Employment or Leadership Position - GlaxoSmithKline (U)
Stock Ownership - GlaxoSmithKline
A. Jonson
No relevant relationships to disclose
D. Richards
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. Cookson
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
W. M. F. Lee
No relevant relationships to disclose
C. Dive
No relevant relationships to disclose
K. M. Fife
No relevant relationships to disclose
D. I. Jodrell
No relevant relationships to disclose
T. Eisen
No relevant relationships to disclose